Market Performance: U.S. stocks opened lower, with the Nasdaq Composite dropping over 150 points, while the Dow and S&P 500 also experienced declines. Energy shares rose by 0.6%, but communication services stocks fell by 1.2%.
Walt Disney Co. Earnings: Disney's shares fell approximately 5% after reporting fiscal Q4 2025 results, with adjusted EPS of $1.11 beating estimates, but revenue remained flat at $22.5 billion, missing analyst forecasts.
Notable Stock Movements: Mersana Therapeutics saw a 207% increase in shares after announcing an acquisition, while Korro Bio's shares plummeted 79% following disappointing financial results and a decision to wind down R&D activities.
Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 down 0.2%, while Asian markets closed higher, led by gains in Japan's Nikkei 225 and Hong Kong's Hang Seng.
Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 56.60 USD with a low forecast of 7.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 56.60 USD with a low forecast of 7.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
8 Hold
0 Sell
Hold
Current: 8.800
Low
7.00
Averages
56.60
High
180.00
Current: 8.800
Low
7.00
Averages
56.60
High
180.00
Piper Sandler
Yasmeen Rahimi
Overweight -> Neutral
downgrade
$180 -> $11
Al Analysis
2025-11-13
Reason
Piper Sandler
Yasmeen Rahimi
Price Target
$180 -> $11
Al Analysis
2025-11-13
downgrade
Overweight -> Neutral
Reason
Piper Sandler analyst Yasmeen Rahimi downgraded Korro Bio to Neutral from Overweight with a price target of $11, down from $180.
Oppenheimer
Outperform -> Perform
downgrade
2025-11-13
Reason
Oppenheimer
Price Target
2025-11-13
downgrade
Outperform -> Perform
Reason
Oppenheimer downgraded Korro Bio to Perform from Outperform.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KRRO
Unlock Now
JonesResearch
Buy
to
Hold
downgrade
2025-11-13
Reason
JonesResearch
Price Target
2025-11-13
downgrade
Buy
to
Hold
Reason
JonesResearch downgraded Korro Bio to Hold from Buy.
JonesResearch
Buy
to
Hold
downgrade
2025-11-13
Reason
JonesResearch
Price Target
2025-11-13
downgrade
Buy
to
Hold
Reason
JonesResearch downgraded Korro Bio to Hold from Buy without a price target after the company announced KRRO-110 did not reach target levels of functional alpha-1 antitrypsin. The firm cites the stock's lack of near-term catalysts and failure to demonstrate proof-of-concept for its RNA editing platform for the downgrade.
About KRRO
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
